Viatris Joins Medical Community on World Thrombosis Day 2021 to Encourage Patients to Keep “Eyes Open to Thrombosis”

Viatris, a new global healthcare company, joins the medical community and the World Thrombosis Day organization[1] on the ongoing efforts to increase global awareness of thrombosis; a dedicated campaign has been developed by the World Thrombosis Day organization to help increase awareness – Eyes Open to Thrombosis. The World Thrombosis Day campaign 2021 is active in 110 countries, engaging nearly 3,000 partners such as hospitals, institutions and medical societies.

1 in 4 people worldwide die each year from conditions caused by thrombosis[2]; this is more than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined[3]. At the same time, research suggests that venous thrombo-embolic events are often preventable, and prevention strategies can stop the development of clots in ‘at-risk’ individuals[4].

Prof. Dr. Rupert Bauersachs, Scientific  Leader of the Action Alliance Thrombosis, Germany, said: “More than half of hospitalized patients are at risk of venous thrombo-embolism, which can occur as a result of a current or recent hospital admission for surgery or acute medical illness. Therefore, all physicians should be aware that any hospitalized patient is potentially at risk for blood clots, and it is important that physicians take the necessary time to perform the thrombosis risk assessment, which will drive the appropriate prevention management.”

Jean-Phillipe Verbist, Regional Medical Lead for Thrombosis Viatris, said: “There are therapeutic solutions to tackle venous thrombo-embolism, and at Viatris we support healthcare professionals from prevention to treatment of the disease, as well as on disease awareness. Viatris’ goal is to contribute to diminishing preventable suffering or death due to thrombo-embolism.”

Viatris in Thrombosis

Viatris is commercializing thrombosis portfolio [in country], as part of an agreement signed in September 2020 to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited’s thrombosis business in Europe.

With the thrombosis portfolio, Viatris is one of the largest suppliers of these products in Europe. /[add In country position]. Across Europe, Viatris provides almost 100 million syringes of treatment to patients every year[5].

Viatris offers a full portfolio of injectable anticoagulants, offering a broad range of indications: from venous thrombosis prophylaxis and treatment, to acute coronary syndrome, superficial vein thrombosis or heparin-induced thrombocytopenia.

This portfolio bolsters Viatris’ existing commercial infrastructure to further expand access to complex injectable therapies.

Preventing thromboembolism for hospitalized patients:

• Patients hospitalized with medical conditions who have congestive heart failure, chronic obstructive lung disease, cancer, a history of venous thromboembolism, or certain other conditions are at increased risk of venous thromboembolism while they are hospitalized.
• The American Society of Hematology (ASH) evidence-based Clinical Practice Guidelines (2018) recommends thromboprophylaxis of high-risk medical patients while they are hospitalized – and not only for patients undertaking a surgery.
• Venous thromboembolism (VTE) remains highly prevalent in medically ill patients, and often leads to increased mortality and cost burden during hospitalization and post-discharge. Nearly half of all VTEs occur during or after hospitalization, with pulmonary embolism accounting for 10% of inpatient mortality[6].
• It is not well recognized that the risk of VTE in many hospitalized medically ill patients is at least as high as in populations after surgery. This may partly be attributed to the clinically silent nature of VTE in many patients, and the difficulty in predicting which patients might develop symptoms or fatal pulmonary embolism.
• Appropriate prophylaxis in high-risk medically ill patients has been shown to reduce risk of VTE and related mortality. Despite current evidence-based guidelines, VTE prophylaxis has been under-used[7].
• For hospitalized medical patients who are acutely ill at increased risk of thrombosis, anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH), unfractionated heparin, or fondaparinux was recommended by ASH in 2018[8].
• In addition to disease burden, VTE can cause significant global economic burden. Multiple diagnostic tests and treatments, prolonged hospital stay and follow-up care – including recurrent; for example, in the U.K., VTE costs the National Health Service €640 million per year[9]. [include local data if available]

More Key Facts about Thrombosis

• Every year, there are approximately 10 million cases of venous thromboembolism (VTE) worldwide[10];
• In Europe only, there are 544,000 VTE-related deaths every year[11].
• 50% of medically ill patients hospitalized are at risk of VTE; when preventive measures are used, VTE risk is reduced by 50-60%[12]
• Thrombosis is frequent in men and older patients[13]

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®.  Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 40,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.